Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

June 2, 2015

Primary Completion Date

August 31, 2018

Study Completion Date

February 28, 2019

Conditions
Bladder Cancer
Interventions
BIOLOGICAL

CG0070

Trial Locations (17)

12061

Premier Medical Group of the Hudson Valley, Poughkeepsie

27157

Wake Forest University School of Medicine, Winston-Salem

32610

UF Health Cancer Center, Gainesville

37232

Vanderbilt University Medical Center, Dept. of Urologic Surgery, Nashville

45212

The Urology Group, Cincinnati

48084

Michigan Institute of Urology, P.C., Troy

53226

Medical College of Wisconsin, Milwaukee

60637

University of Chicago, Chicago

68114

Adult Pediatric Urology and Urogynecology, PC, Omaha

68130

GU Research Network/ The Urology Center, Omaha

85032

BCG Oncology, Phoenix

85704

Arizona Institute of Urology, Tucson

90095

Institute of Urologic Oncology at UCLA, Los Angeles

92093

University of California, San Diego, San Diego

92868

UC Irvine Medical Center, Orange

99503

Alaska Clinical Research Center, Anchorage

08837

Premier Urology Group, LLC., Edison

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CG Oncology, Inc.

INDUSTRY